Clearside Biomedical (NASDAQ:CLSD) Research Coverage Started at Weiss Ratings

Weiss Ratings initiated coverage on shares of Clearside Biomedical (NASDAQ:CLSD) in a research note issued to investors on Saturday morning,Weiss Ratings reports. The firm issued a sell (e+) rating on the stock.

CLSD has been the topic of several other reports. Stifel Nicolaus lowered shares of Clearside Biomedical from a “buy” rating to a “hold” rating and set a $30.00 target price on the stock. in a report on Friday, July 18th. Chardan Capital lowered shares of Clearside Biomedical from a “buy” rating to a “neutral” rating in a report on Friday, July 18th. Needham & Company LLC lowered shares of Clearside Biomedical from a “moderate buy” rating to a “hold” rating and set a $45.00 price objective on the stock. in a report on Thursday, July 17th. Jones Trading lowered shares of Clearside Biomedical from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Finally, Wall Street Zen upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Saturday, October 25th. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $63.00.

Clearside Biomedical Stock Performance

CLSD opened at $4.09 on Friday. The firm’s fifty day moving average is $4.36 and its two-hundred day moving average is $8.41. The firm has a market cap of $21.42 million, a PE ratio of -0.74 and a beta of 2.05. Clearside Biomedical has a twelve month low of $3.32 and a twelve month high of $17.40.

Clearside Biomedical (NASDAQ:CLSD) last posted its earnings results on Friday, August 8th. The company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($1.80) by $0.90. The firm had revenue of $0.49 million during the quarter, compared to analyst estimates of $0.50 million. Equities analysts forecast that Clearside Biomedical will post -0.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Clearside Biomedical

A hedge fund recently bought a new stake in Clearside Biomedical stock. Apollon Wealth Management LLC purchased a new stake in Clearside Biomedical, Inc. (NASDAQ:CLSD) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 23,586 shares of the company’s stock, valued at approximately $94,000. Apollon Wealth Management LLC owned about 0.45% of Clearside Biomedical at the end of the most recent quarter. Institutional investors own 18.75% of the company’s stock.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.